Table 1.
Pembrolizumab outcomes cohort by PD-L1 RNA-seq expression status (n = 102).
| RNA High (≥75 Rank) n = 69 (67.7) |
RNA Not High (<75 Rank) n = 33 (32.3) |
Total (n = 102) | ||
|---|---|---|---|---|
| PD-L1 IHC status | High (≥50% TPS) | 64 (92.8) | 20 (60.6) | 84 (82.3) |
| Low (1–49% TPS) | 5 (7.2) | 13 (29.4) | 18 (17.7) | |
| Age (mean, years) | 70 | 70 | 70 | |
| Sex | Female | 39 (56.5) | 20 (60.6) | 59 (57.8) |
| Male | 30 (43.5) | 13 (39.4) | 43 (42.2) | |
| Ever smoker (yes) | 61 (88.4) | 30 (90.9) | 91 (89.2) | |
| Histology | Non-Squamous | 61 (88.4) | 22 (66.7) | 83 (81.4) |
| Squamous | 8 (11.6) | 11 (33.3) | 19 (18.6) | |
| Tissue Site | Primary | 34 (49.3) | 21 (63.8) | 55 (53.9) |
| Metastatic | 35 (50.7) | 12 (36.4) | 47 (46.1) | |
| Performance status (weighted) |
<1 | 22 (31.9) | 3 (9.1) | 25 (24.5) |
| 1 to <2 | 39 (56.5) | 24 (72.7) | 63 (61.8) | |
| 2 to <4 | 6 (8.7) | 5 (15.2) | 11 (10.8) | |
| Brain metastases (yes) | 11 (15.9) | 4 (12.1) | 15 (14.7) | |
| Pembrolizumab line of treatment | 1 | 59 (85.5) | 27 (81.8) | 86 (84.3) |
| 2 | 8 (11.6) | 4 (12.1) | 12 (11.8) | |
| ≥3 | 2 (2.9) | 2 (6.1) | 4 (3.9) | |
| Prior treatment history (yes) | Chemotherapy | 8 (11.6) | 5 (15.2) | 13 (12.7) |
| Targeted therapy | 1 (1.4) | 2 (6.0) | 3 (2.9) | |
| Immunotherapy | 2 (2.8) | 0 (0.0) | 2(2.0) | |